NasdaqGS:ZYMEBiotechs
Zymeworks (ZYME) Stock Could Be 42.3% Undervalued After Cryo EM Breakthrough
Why Zymeworks’ Cryo‑EM Breakthrough Matters for the Stock
Zymeworks (ZYME) just reported a collaboration with Gandeeva Therapeutics that used high resolution cryo electron microscopy to map a small antigen bound to a Zymeworks antibody, sharpening insight into antibody epitope binding.
For you as a shareholder or potential investor, the key point is that this work goes beyond a headline partnership announcement and delivers specific structural data, including a 2.6 Å view of nine amino acids...